Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Piotroski F-Score: 3
Altman Z-Score: -64.31
Beneish M-Score: -1.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROA % -1730.59
GNBT's ROA % is ranked lower than
99% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. GNBT: -1730.59 )
Ranked among companies with meaningful ROA % only.
GNBT' s ROA % Range Over the Past 10 Years
Min: -1730.59  Med: -108.18 Max: -0.02
Current: -1730.59
-1730.59
-0.02
ROC (Joel Greenblatt) % -3681555.56
GNBT's ROC (Joel Greenblatt) % is ranked lower than
100% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. GNBT: -3681555.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNBT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3681555.56  Med: -1644.62 Max: 711.11
Current: -3681555.56
-3681555.56
711.11
3-Year EBITDA Growth Rate -44.70
GNBT's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. GNBT: -44.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GNBT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.6  Med: -28.5 Max: 101.9
Current: -44.7
-67.6
101.9
3-Year EPS without NRI Growth Rate -44.20
GNBT's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. GNBT: -44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GNBT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.4  Med: -26.45 Max: 46.3
Current: -44.2
-66.4
46.3
GuruFocus has detected 2 Warning Signs with Generex Biotechnology Corp $GNBT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNBT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CTBO, OTCPK:TIKRF, AMEX:IMUC, OTCPK:CBBT, OTCPK:KNBIF, OTCPK:BIEI, OTCPK:BTHE, OTCPK:ICOTF, OTCPK:GRSO, OTCPK:TSOI, OTCPK:CRXM, OTCPK:GOVX, OTCPK:LCAR, OTCPK:SGBI, OTCPK:HDVY, OTCPK:ARNI, OTCPK:CTTC, OTCPK:PPCB, OTCPK:CAPS, NAS:OPXA » details
Traded in other countries:GB8A.Germany,
Headquarter Location:Canada
Generex Biotechnology Corp is engaged in the research and development of drug delivery systems and technologies.

Generex Biotechnology Corporation was incorporated in Delaware in September 1997. The Company is engaged mainly in the research and development of drug delivery systems and technologies. It has identified several large molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormones. It has focused its development efforts mainly on one pharmaceutical product, Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its proprietary hand-held aerosol spray applicator known as RapidMist. Its wholly-owned subsidiary, Antigen, concentrates on developing proprietary vaccine formulations that work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self-proteins and allergens). Its immunomedicine products are based on two platform technologies and are in the early stages of development. The Company has vaccine development efforts underway for seasonal influenza virus, HIV, HPV, melanoma, ovarian cancer, allergy and Type I diabetes mellitus. Its main competitors include: Pfizer, Eli Lilly, Novo Nordisk, Merck & Co., Inc., GlaxoSmithKline PLC, Novartis, Inc., and MedImmune Inc.

Ratios

vs
industry
vs
history
EV-to-EBIT -0.17
GNBT's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 22.66 vs. GNBT: -0.17 )
Ranked among companies with meaningful EV-to-EBIT only.
GNBT' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.1  Med: -2.1 Max: -0.1
Current: -0.17
-10.1
-0.1
EV-to-EBITDA -0.17
GNBT's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.28 vs. GNBT: -0.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNBT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.4  Med: -2.3 Max: -0.17
Current: -0.17
-81.4
-0.17
Current Ratio 0.17
GNBT's Current Ratio is ranked lower than
100% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GNBT: 0.17 )
Ranked among companies with meaningful Current Ratio only.
GNBT' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.93 Max: 36.05
Current: 0.17
0.01
36.05
Quick Ratio 0.17
GNBT's Quick Ratio is ranked lower than
100% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GNBT: 0.17 )
Ranked among companies with meaningful Quick Ratio only.
GNBT' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.79 Max: 36.05
Current: 0.17
0.01
36.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.20
GNBT's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. GNBT: -16.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNBT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -71  Med: -27.5 Max: 0
Current: -16.2
-71
0

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -588.24
GNBT's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. GNBT: -588.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNBT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -691.4  Med: -48.1 Max: -9.9
Current: -588.24
-691.4
-9.9

More Statistics

EPS (TTM) $ -59.02
Beta-0.37
Short Percentage of Float2.74%
52-Week Range $2.00 - 20.00
Shares Outstanding (Mil)1.07
» More Articles for GNBT

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: TDG, GNBT, ADGE, HFC, AMSWA Jul 02 2012 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Weekly CFO Buys Highlight: GNBT, CTTC, COIN, AUMN, SOMH Oct 31 2010 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 
Generex Biotechnology Corp. (GNBT) CEO Anna E Gluskin buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) CFO Rose C Perri buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
Generex Announces Reverse Stock Split Mar 14 2017
Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017 Feb 21 2017
Generex Announces Elimination of Outstanding Derivative Securities Feb 15 2017
Generex Provides Update on Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc. Feb 09 2017
Generex Announces Investor Conference Call Jan 30 2017
Hema Diagnostic Systems Announces the Sepsis Development Team Jan 30 2017
Hema Diagnostic Systems Announces the Introduction of the New RAPID 1-2-3 HEMA EXPRESS HIV 1/2 P24... Jan 26 2017
ADDING MULTIMEDIA Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors Jan 25 2017
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology... Jan 25 2017
Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV... Jan 24 2017
Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology... Jan 24 2017
Hema Diagnostic Systems Announces the Program for Development and Design of a Multiplex Assay for... Jan 23 2017
Generex Announces Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc. Jan 23 2017
Generex Announces Closing of Acquisition of Controlling Equity Interest in Hema Diagnostic Systems Jan 23 2017
Exploring Market Correlations -- Comprehensive Research on Hydrophi Technologies Group, Generex... Feb 02 2016
Hema Diagnostic Systems, L.L.C. Announces the Final Validation Process for a New Rapid Anthrax Ab... Oct 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}